EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential

Osama Sobhi Moaket, Sarah Eyad Obaid iD, Fawaz Eyad Obaid iD, Yusuf Abdulkarim Shakeeb iD, Samir Mohammed Elsharief, Afrin Tania, Radwan Darwish iD, Alexandra E Butler iD, Abu Saleh Md Moin iD

International Journal of Molecular Sciences · 05.11.2025 · 26 (21) · 10743

DOI: 10.3390/ijms262110743 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2025. Verfasst von Osama Sobhi Moaket und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen P.O. Box 15503, Bahrain. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Neurodegenerative Diseases, Brain, Neuroprotective Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, and depression, are marked by progressive neuronal dysfunction and loss, yet current treatments remain largely symptomatic with limited disease-modifying efficacy. Glucagon-like peptide-1 (GLP-1), an incretin hormone traditionally associated with metabolic regulation, has emerged as a promising neuroprotective agent. Its receptor, GLP-1R, is expressed in key brain regions implicated in cognition, emotion, and motor control, including the hippocampus, frontal cortex, and substantia nigra. GLP-1R agonists (GLP-1RAs) activate multiple intracellular signaling cascades—cAMP/PKA, PI3K/Akt, and MAPK pathways—that collectively promote neuronal survival, enhance synaptic plasticity, reduce oxidative stress, inhibit apoptosis, and modulate neuroinflammation. These agents also regulate autophagy, promote remyelination, and reprogram microglial phenotypes toward anti-inflammatory states. Preclinical models have shown that GLP-1RAs reduce amyloid-β and tau pathology in AD, preserve dopaminergic neurons in PD, protect astrocytes and neural progenitors after ischemic stroke, and alleviate depressive behaviors. Notably, GLP-1RAs such as liraglutide, exenatide, and dulaglutide can cross the blood–brain barrier and have demonstrated safety and potential efficacy in early-phase clinical trials. These studies report attenuation of cortical atrophy, preservation of cerebral glucose metabolism, and improvements in quality of life, though changes in core AD biomarkers remain inconclusive. Ongoing large-scale trials (e.g., EVOKE, ELAD) are further exploring their therapeutic impact. This review consolidates the mechanistic basis and translational potential of GLP-1RAs in age-related neurodegenerative diseases, highlighting both their promise and the challenges that must be addressed in future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Neurodegenerative DiseasesBrainNeuroprotective AgentsHumansAnimalsGlucagon-Like Peptide-1 ReceptorAlzheimer DiseaseGlucagon-Like Peptide-1 Receptor AgonistsSignal Transduction

Stichwörter der Autor:innen

Alzheimer’s diseaseGLP-1 receptor agonists (GLP-1RAs)Parkinson’s diseaseclinical trialsneurodegenerationneuroinflammationstrokesynaptic plasticity

Substanzen

Glucagon-Like Peptide 1Neuroprotective AgentsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen P.O. Box 15503, Bahrain.
  • Research Department, Royal College of Surgeons in Ireland-Bahrain, Busaiteen P.O. Box 15503, Bahrain.

ORCID-Profile: Sarah Eyad Obaid, Fawaz Eyad Obaid, Yusuf Abdulkarim Shakeeb, Radwan Darwish, Alexandra E Butler, Abu Saleh Md Moin

Zitieren

APA

Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025). GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential. International Journal of Molecular Sciences, 26(21), 10743. https://doi.org/10.3390/ijms262110743

Vancouver

Moaket OS, Obaid SE, Obaid FE, Shakeeb YA, Elsharief SM, Tania A, et al. GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential. International Journal of Molecular Sciences. 2025;26(21):10743. doi:10.3390/ijms262110743

BibTeX
@article{Moaket2025,
  author = {Moaket, Osama Sobhi and Obaid, Sarah Eyad and Obaid, Fawaz Eyad and Shakeeb, Yusuf Abdulkarim and Elsharief, Samir Mohammed and Tania, Afrin and Darwish, Radwan and Butler, Alexandra E and Moin, Abu Saleh Md},
  title = {GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {21},
  pages = {10743},
  doi = {10.3390/ijms262110743}
}
Kostenlos starten →